Protalix Biotherapeutics and Secarna Pharmaceuticals Form Collaboration and Option Agreement
Thursday, December 18, 2025
Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop new antisense oligonucleotide (ASO) therapies for rare kidney diseases.
Under the agreement, the two companies will work together on the discovery of ASO treatments targeting multiple rare renal conditions. Protalix has identified several biological targets that play an important role in these diseases, while Secarna will use its proprietary AI-enabled OligoCreator® platform to design and evaluate ASO candidates against these targets.
The collaboration aims to combine the research and development strengths of both companies to advance selected programmes from the preclinical stage into clinical trials. As part of the agreement, Secarna has granted Protalix an option to obtain an exclusive, worldwide licence to further develop, manufacture and commercialise the resulting therapeutic programmes, subject to milestone and royalty payments.
This partnership marks Protalix’s expansion into rare kidney diseases using RNA-based technologies, in line with its updated research strategy. The company plans to build on its experience in rare disease drug development to broaden its pipeline and address areas of high unmet medical need.
For Secarna, the collaboration provides an opportunity to apply its antisense technology expertise alongside a partner with a strong track record in advancing rare disease treatments to patients globally. Together, the companies aim to develop targeted and differentiated therapies for people living with severe renal disorders.
Source: prnewswire.com
